Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

Hepatology

Volumn 30, Issue 2, 1999, Pages 567-572

  Liaw, Yun Fan ^a,b   Chien, Rong Nan ^a   Yeh, Chau Ting ^a   Tsai, Sun Lung ^a   Chu, Chia Ming ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; VIRUS REPLICATION;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CONSERVED SEQUENCE; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION;

EID: 0032783679     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300221     Document Type: Article

References (20)

1. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88:8495-8499.
2. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N EnglJ Med 1995;333:1657-1661.
3. Nevens F, Main J, Honkoop P, Tyrrell DL, Barbar J, Sullivan M, Fevery J, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258-1263.
4. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
5. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplanted recipients with lamivudine. HEPATOLOGY 1996;24:711-713.
6. Bartholomew M, Jansen RW, Jeffers LF, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
7. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Trell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. HEPATOLOGY 1996;24:714-717.
8. Honkoop P, Niesters HGM, de Man RAM, Osterhaus ADME, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B; Incidence and patterns. J Hepatol 1997;26:1393-1395.
9. Buti M, Jardi R, Cotrina M, Rodriguez-Frias F, Esteban R, Guardia J. Transient emergence of hepatitis B variants in a patients with chronic hepatitis B resistant to lamivudine. J Hepatol 1998;28:510-513.
10. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. HEPATOLOGY 1998;27:1711-1717.
11. Liaw YF, Lai CL, Leung NWY, Chang TT, Guan R, Tai DI et al Two-year lamivudine therapy in chronic hepatitis B infection: Results of a placebo controlled multi-center study in Asia. Gastroenterology 1988;114:A1289.
12. Liaw YE Acute exacerbation and superinfection in patients with chronic viral hepatitis. J Formos Med Assoc 1995;94:521-528.
13. Chu CM, Yeh CT, Sheen IS, Liaw YE Subcellular localization of hepatitis B core antigen in relation to hepatocyte regeneration in chronic hepatitis B. Gastroenterology 1995;109:1926-1932.
14. Yeh CT, Chu CM, Liaw YH Progression of the proportion of hepatitis B virus precore stop mutant following acute superinfection of hepatitis C. J Gastroenterol Hepatol 1998;13:19-24.
15. deMan RA, Bartholomeusz AI, Niesters HGM, Zonderan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 1998;29:669-675.
16. Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, ChangChien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983;84:216-219.
17. Liaw YF, Chu CM, Huang MJ, Sheen IS, Yang CY, Lin DY. Determinants for hepatitis B e antigen clearance in chronic type B hepatitis. Liver 1984;4;301-306.
18. Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibodypositive patients. HEPATOLOGY 1987;7:20-23.
19. Liaw YF, Tsai SL. Pathogenesis and clinical significance of acute exacerbations and remissions in patients with chronic hepatitis B virus infection. Viral Hep Rev 1997;3:143-154.
20. Davenport MP. Antagonists or altruists: do viral mutants modulate T-cell responses? Immunol Today 1995;16:432-436.